Roell W, Goedje O, Vetter H O, Schmitz C, Dewald O, Reichart B
Department of Cardiac Surgery, Ludwig-Maximilians-University, Grosshadern Medical Center, Munich, Germany.
Eur J Cardiothorac Surg. 1997 Jun;11(6):1045-51. doi: 10.1016/s1010-7940(97)00094-8.
Since its clinical introduction, the Novacor left ventricular assist system (LVAS) has proved to be a reliable and safe method for bridging to cardiac transplantation. To find out whether univentricular assistance is sufficient in patients with severe global heart failure, multi organ monitoring using the COLD system was performed.
In seven patients (mean age 38.8 years), the wearable Novacor system N100 was implanted. Preoperatively, during the first 72 h thereafter and before heart transplantation right and left ventricular cardiac output, right ventricular ejection fraction, pulmonary-, intrathoracic-and total blood volume, extravascular lung water and excretory liver function were monitored by means of double indicator dilution technique with the COLD system. Conventional hemodynamic parameters have also been documented.
During left ventricular assistance, both pulmonary and systemic arterial cardiac outputs increased significantly (Student's t-test, P < 0.05). Right ventricular ejection fraction rose from 17 to 26%, preoperatively elevated pulmonary and intrathoracic blood volumes and extravascular lung water fell significantly to normal ranges. Total blood volume remained constant, excretory liver function improved markedly.
Pulmonary cardiac output improves due to the reduced right ventricular afterload by unloading the impaired left ventricle with the Novacor pump. The drop in pulmonary blood volume, intrathoracic blood volume and extravascular lung water also indicates a decrease of pulmonary congestion. Since total blood volume remains unchanged, a volume shift to the systemic circulation is suggested, resulting in an improved splanchnic perfusion as demonstrated by a better excretory liver function. In the absence of primary pulmonary hypertension, treatment of global heart failure with a left ventricular assist device is possible. The COLD system is a useful tool for managing this patient group during the postoperative period.
自临床应用以来,诺瓦科尔左心室辅助系统(LVAS)已被证明是一种可靠且安全的心脏移植过渡方法。为了确定单心室辅助对严重全心衰患者是否足够,使用COLD系统进行了多器官监测。
对7例患者(平均年龄38.8岁)植入了可穿戴的诺瓦科尔N100系统。术前、术后最初72小时内及心脏移植前,通过COLD系统采用双指示剂稀释技术监测右心室和左心室心输出量、右心室射血分数、肺血容量、胸腔内血容量、总血容量、血管外肺水和肝脏排泄功能。还记录了常规血流动力学参数。
在左心室辅助期间,肺循环和体循环动脉心输出量均显著增加(学生t检验,P<0.05)。右心室射血分数从17%升至26%,术前升高的肺血容量和胸腔内血容量以及血管外肺水显著下降至正常范围。总血容量保持不变,肝脏排泄功能明显改善。
通过诺瓦科尔泵卸载受损的左心室,降低了右心室后负荷,从而改善了肺循环心输出量。肺血容量、胸腔内血容量和血管外肺水的下降也表明肺淤血减轻。由于总血容量保持不变,提示存在向体循环的容量转移,肝脏排泄功能改善表明内脏灌注得到改善。在无原发性肺动脉高压的情况下,使用左心室辅助装置治疗全心衰是可行的。COLD系统是术后管理该患者群体的有用工具。